PMID- 20448223
OWN - NLM
STAT- MEDLINE
DCOM- 20100812
LR  - 20220409
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Print)
IS  - 0032-5473 (Linking)
VI  - 86
IP  - 1015
DP  - 2010 May
TI  - Iron deficiency anaemia can be improved after eradication of Helicobacter pylori.
PG  - 272-8
LID - 10.1136/pgmj.2009.089987 [doi]
AB  - BACKGROUND: Recent guidelines on iron deficiency anaemia (IDA) have confirmed the 
      aetiological role of Helicobacter pylori (H pylori), but the relationship still 
      remains controversial. METHODS: Starting in May 2009, searches of the following 
      databases were undertaken: Medline (1966 to April 2009), Embase (1980 to April 
      2009), the Cochrane library (1800 to June 2008), Cochrane Central Register of 
      Controlled Trials, Premedline, Healthstar, CBMdisc and the Chinese National 
      Knowledge Infrastructure Database (January 1970 to April 2009). Changes in 
      haemoglobin (Hb) concentrations and serum ferritin (SF) concentrations were 
      recorded for intervention and control groups. The meta-analysis used random 
      effect models and subgroup analyses were performed to explain heterogeneity. 
      RESULTS: Eight studies met the inclusion criteria. All studies were performed in 
      Asia, an area with a high incidence of IDA and H pylori. The pooled analysis of 
      eight studies showed that H pylori eradication therapy can improve IDA, since 
      changes in Hb and SF concentrations in the intervention groups were higher than 
      in controls. The weighted mean difference (WMD) of Hb was 12.88 g/l (95% CI 6.03 
      to 19.74 g/l, p<0.00001); the WMD of SF was 10.05 mug/l (95% CI 5.48 to 14.63 
      mug/l, p<0.00001). CONCLUSIONS: H pylori eradication therapy combined with iron 
      administration is more effective than iron administration alone for the treatment 
      of IDA. Eradication therapy has different effects on adults and children. Bismuth 
      based triple therapy has a better response in terms of increased Hb and SF 
      concentrations than proton pump inhibitor (PPI) based triple therapy.
FAU - Huang, Xiaolu
AU  - Huang X
AD  - Department of Ultrasonic, Shanghai No.9 People's Hospital, Shanghai Jiaotong 
      University School of Medicine, Shanghai 200011, China. pxiong6@126.com.
FAU - Qu, Xinhua
AU  - Qu X
FAU - Yan, Weili
AU  - Yan W
FAU - Huang, Youliang
AU  - Huang Y
FAU - Cai, Mingci
AU  - Cai M
FAU - Hu, Bing
AU  - Hu B
FAU - Wu, Lianming
AU  - Wu L
FAU - Lin, Hai
AU  - Lin H
FAU - Chen, Zhiwei
AU  - Chen Z
FAU - Zhu, Cuiying
AU  - Zhu C
FAU - Lu, Lungen
AU  - Lu L
FAU - Sun, Xu
AU  - Sun X
FAU - Rong, Lan
AU  - Rong L
FAU - Jiang, Yibin
AU  - Jiang Y
FAU - Sun, Dayu
AU  - Sun D
FAU - Zhong, Liang
AU  - Zhong L
FAU - Xiong, Ping
AU  - Xiong P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anemia, Iron-Deficiency/*drug therapy
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Bismuth/therapeutic use
MH  - Child
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Middle Aged
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC2981025
COIS- Competing interests: None.
EDAT- 2010/05/08 06:00
MHDA- 2010/08/13 06:00
PMCR- 2010/05/06
CRDT- 2010/05/08 06:00
PHST- 2010/05/08 06:00 [entrez]
PHST- 2010/05/08 06:00 [pubmed]
PHST- 2010/08/13 06:00 [medline]
PHST- 2010/05/06 00:00 [pmc-release]
AID - 86/1015/272 [pii]
AID - postgradmedj89987 [pii]
AID - 10.1136/pgmj.2009.089987 [doi]
PST - ppublish
SO  - Postgrad Med J. 2010 May;86(1015):272-8. doi: 10.1136/pgmj.2009.089987.